Level C· Early human research exploring benefitsRetrospective StudyPubMed

Reliable bioelectrical impedance analysis estimate of fat-free mass in liver, lung, and heart transplant patients.

Kyle UG., Genton L., Mentha G., Nicod L., Slosman DO., Pichard C.

Retrospective Study with a reported sample of 159 on Systemic / IV, published in JPEN J Parenter Enteral Nutr (2001) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
JPEN J Parenter Enteral Nutr (2001)
Country
United States
Reported sample size
159
Source database
PubMed
PMID
11284469
DOI
10.1177/014860710102500245

Abstract (original English)

Bioelectrical impedance analysis (BIA) can be valuable in evaluating the fat-free (FFM) and fat masses (FM) in patients, provided that the BIA equation is valid in the subjects studied. The purpose of the clinical evaluation was to evaluate the applicability of a single BIA equation to predict FFM in pre- and posttransplant patients and to compare FFM and FM in transplant patients with healthy controls. Pre- and posttransplant liver, lung, and heart patients (159 men, 86 women) were measured by two methods-50-kHz BIA-derived FFM (FFM(BIA)) by Xitron instrument and DXA-derived FFM (FFM(DXA)) by Hologic QDR-4500 instrument-and compared with healthy controls (196 men, 129 women), aged 20 to 79 years. The high correlation coefficient (r = .974), small bias (0.3 +/- 2.3 kg), and small SEE (2.3 kg) suggest that BIA using the GENEVA equation is able to predict FFM in pre- and posttransplant patients. The study shows that the lower weight seen in transplant men and women than in controls was due to lower FFM, which was partially offset by higher FM in men but not in women. Furthermore, the higher weights in posttransplant than in pretransplant patients were due to higher FM and % FM that was confirmed by lower FFM/FM ratio in posttransplant patients. Single 50-kHz frequency BIA permits measurement of FFM in pre- and posttransplant patients.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Absorptiometry, PhotonAdipose TissueAdultAgedBody CompositionCase-Control StudiesElectric ImpedanceFemaleHeart TransplantationHumans

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research